# Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

> **NCT04858776** · PHASE2 · RECRUITING · sponsor: **Mercator MedSystems, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Iliofemoral; Thrombosis

## Interventions

- **COMBINATION_PRODUCT:** Perivascular dexamethasone
- **COMBINATION_PRODUCT:** Perivascular sham

## Key facts

- **NCT ID:** NCT04858776
- **Lead sponsor:** Mercator MedSystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-08
- **Primary completion:** 2025-05-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858776, "Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04858776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*